LONG-TERM SAFETY AND EFFICACY OF TAMSULOSIN FOR THE TREATMENT OF LOWER URINARY TRACT SYMPTOMS ASSOCIATED WITH BENIGN PROSTATIC HYPERPLASIA
|
|
- Avice Goodwin
- 6 years ago
- Views:
Transcription
1 /03/ /0 Vol. 170, , August 2003 THE JOURNAL OF UROLOGY Printed in U.S.A. Copyright 2003 by AMERICAN UROLOGICAL ASSOCIATION DOI: /01.ju fd LONG-TERM SAFETY AND EFFICACY OF TAMSULOSIN FOR THE TREATMENT OF LOWER URINARY TRACT SYMPTOMS ASSOCIATED WITH BENIGN PROSTATIC HYPERPLASIA PERINCHERY NARAYAN,* CHRISTOPHER P. EVANS AND TIMOTHY MOON* From the North Florida Research Institute, Inc., Gainesville, Florida, Department of Urology, University of California, Davis School of Medicine, Sacramento, California, and Division of Urology, University of Wisconsin, Madison, Wisconsin ABSTRACT Purpose: We evaluated the long-term (up to 6 years) safety and efficacy of the selective 1A-adrenoceptor antagonist tamsulosin in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia. Materials and Methods: A total of 609 patients were enrolled in a 4-year multicenter open label extension study. Subjects entered the study after completion of a 1-year open label trial that included patients who previously completed up to 57 weeks of double-blind, placebo controlled studies. Maintenance doses (0.4 or mg daily) established in the 1-year study were continued. Efficacy and safety were assessed every 3 months. Primary efficacy evaluations were changes from baseline maximum urine flow rate and total American Urological Association symptom index, and the responder rates for those 2 end points. Secondary end points were changes in American Urological Association subset scores, Boyarsky symptom scores, average urine flow rate, post-void residual urine volume, quality of life index and investigator global assessment. Results: Of the 609 patients who entered the 4-year extension study 159 had a 2-year or greater prior experience with tamsulosin, yielding a potential 6-year experience on the medication. Of this 159 patient subset 109 completed the whole 6 years. Initial rapid improvements from baseline in primary and secondary end points were maintained each year throughout the duration of the study. Tamsulosin was well tolerated, confirming the safety profile demonstrated in earlier studies. Orthostatic hypotension was observed in 1.3% of the patients. Conclusions: This study demonstrates the sustained efficacy, safety and excellent long-term tolerability of tamsulosin for up to 6 years in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia. KEY WORDS: prostate, prostatic hyperplasia, urination disorders, adrenergic alpha-antagonists Pathological signs of benign prostatic hyperplasia (BPH) occur in 8% of men in the fourth decade of life with the prevalence steadily increasing to greater than 70% of men in the seventh decade of life. 1 As the United States population ages, the number of men with BPH increases, creating a greater demand for effective and safe treatments. Current treatment options include surgical and pharmacological interventions. Tamsulosin, which has been available in the United States since 1997, has proved to be effective for treating lower urinary tract symptoms (LUTS) due to BPH. 2 4 The relative lack of cardiovascular side effects and lack of interactions with antihypertensives associated with tamsulosin therapy is probably due to its subtype selectivity for 1A and 1D-adrenergic receptors. 5, 6 It is the first drug targeted specifically to treat only LUTS associated with BPH. Published pivotal double-blind studies have demonstrated the efficacy and tolerability of tamsulosin for up to 1 year. 2 4 An extension study showed similar results for up to 2 years. 7 We describe a long-term 4-year extension study that enabled patients to continue tamsulosin treatment for up to 6 years (fig. 1). Accepted for publication March 21, * Financial interest and/or other relationship with Boehringer- Ingelheim and Sanofi. Financial interest and/or other relationship with Boehringer- Ingelheim and Astra-Zeneca. 498 MATERIALS AND METHODS Patients. Eligible patients included in this study (527.2) were men 45 years or older who had completed a previous 1-year open label extension trial of tamsulosin (US93-04). 7 This trial recruited patients from 3 shorter double-blind studies, namely US92-03A (17 weeks), 3 US92-03B (40-week extension of US92-03A) 4 and US93-01 (17 weeks). 2 Study US93-04 included patients from active and placebo groups from the previous studies, a number of patients enrolled but not randomized and a few who had had experience with tamsulosin in other trials. 7 Patients agreed to continue established treatment maintenance doses (0.4 or 0.8 mg daily), make required clinic visits 3 months 7 days apart throughout the 4-year extension and provide informed consent. Inclusion/exclusion criteria. Exclusion criteria were biopsy evidence of prostate cancer following a prostate specific antigen (PSA) measurement of greater than 4.0 ng/ml or positive digital rectal examination or evidence of cancer on transrectal ultrasound. Other reasons for exclusion included acute urinary retention (AUR) or urinary tract infection, renal dysfunction, abnormal hemoglobin, leukocytes or liver enzymes, postural symptoms, diastolic blood pressure below 60 mm Hg or tachycardia to greater than 120 beats per minute, poorly controlled diabetes and poor compliance during the previous study. -Adrenergic agents and anticholinergics were prohibited. Efficacy. Primary efficacy evaluations at each visit were changes from baseline in total American Urological Associa-
2 LONG-TERM SAFETY AND EFFICACY OF TAMSULOSIN 499 FIG. 1. Tamsulosin long-term study. Asterisk represents double-blind, placebo-controlled trial. Of 208 patients 74 were from placebo treated group of US92-03A/B, 104 from placebo treated group of US93-01, 15 from placebo treated group who completed study US92-03A and did not continue to study US92-03B, and 15 who qualified by exceptional enrollment and were on tamsulosin in previous trials. Of 239 patients, 219 on tamsulosin completed study US93-01 and 20 on tamsulsin completed study US92-03A but did not continue to study US92-03B. Total of 162 patients on tamsulosin completed studies US92-03A and US92-03B, and had potential 6-year experience with tamsulosin. tion (AUA) symptom index score (7 questions scored 0 to 5) and maximum urine flow rate (Qmax). Qmax was measured by uroflowmetry and patients voided at least 125 ml. Other primary efficacy evaluations were the percent of total AUA symptom score responders and the percent of total Qmax responders. Secondary efficacy evaluations included changes from baseline in AUA subset scores (obstructive 3 questions, irritative 4 questions, AUA bother score 7 questions, scored 0 to 4), Boyarsky symptom scores (9 urinary symptoms scored 0 to 3), changes from baseline for mean urinary flow rate and investigator global assessment (scored 0 worsened to 4 markedly improved). Other criteria included uroflowmetry, post-void residual urine volume (PVR) and a quality of life (QOL) questionnaire consisting of 5 questions, of which 4 were validated (possible score 13). 8 Safety. Safety assessments at each visit were evaluated for treatment emergent (TE) adverse events (AEs), changes in digital rectal examination and other changes on physical examination (body weight and vital signs). Assessments also included chest x-ray, 12 lead electrocardiogram and clinical laboratory tests (blood chemistry, PSA, hematology and urinalysis). Clinically significant orthostatic hypotension was defined by a decrease in systolic blood pressure of 20 mm Hg or greater, or symptoms with a change in posture. AEs occurring between dose 1 and 28 days after the last dose were classified as TEAEs and categorized by us as probably, possibly or remotely related, or unrelated to the study drug. Serious AEs were classified as any fatal or immediately life threatening clinical experience, permanently or severely disabling event, or event requiring or prolonging hospitalization. The safety population received at least 1 dose of tamsulosin. Safety data were recorded throughout the 4-year extension. The intent to treat (ITT) population received at least 1 dose with efficacy data collected after visit 1. Baseline values were established during the visit prior to the initial tamsulosin dose in patient respective earlier studies. RESULTS A total of 609 patients entered the 4-year extension trial, of whom 5 were excluded due to an incomplete post-baseline safety assessment, so that 604 patients comprised the safety population. Of the 609 men 159 entered with 2 or more years of experience with tamsulosin (potential 6 years of treatment) and of these 609 men 109 completed 6 years. Mean patient age and weight were 58.9 years and pounds, respectively. Of the men 94.9% were white, 4.5% were black and 0.7% were Asian or other. The patient age range was 45 to 79 years and 269 men (44.5%) were 55 to 64 years old. Efficacy analysis. Changes from baseline to the first evaluable assessment after each treatment year were analyzed in the 600 men in the ITT population. Significant improvement from baseline was observed after the completion of each year of exposure for as long as 6 years for change from baseline in total AUA symptom score and change from baseline in Qmax (fig. 2). Mean total AUA symptom score improvement from baseline for the 6 years was 8.1 to 10.9 (p 0.05). Figure 3 shows mean improvements from baseline in the 159 patients who had the potential to receive 6 years of tamsulosin experience. The percent of patients experiencing a 25% or greater decrease in total AUA symptom score from baseline was consistent for the 6 years (71.6% to 80.7%). Mean improvement in Qmax from baseline was 1.01 to 2.29 ml per second (p 0.05). A 30% or greater change was noted in 40% of patients during year 1. Similar percents were sustained for up to 6 years (26.9% to 40.0%). Secondary efficacy evaluations showed statistically significant improvement from baseline during each year of tamsulosin administration (p 0.05, table 1). The investigator global assessment tabulation demonstrated that 85.2% to 96.3% of the patients maintained or increased the improvement shown in previous tamsulosin trials. QOL improvement was also sustained throughout the 6 years. Improvements in PVR relative to baseline (88.0 ml) were between 17.8 and 3.2 ml for all years of tamsulosin administration. Except for years 4 and 6 these changes were statistically significant (p 0.05). Safety analysis. During the 4-year extension infection in 45.5% of cases, accidental injury in 29.8%, rhinitis in 25.7%, pain in 24.8% and pharyngitis in 23.8% were the most frequently observed TEAEs, of which each was reported at least once. Drug related (defined as probably, possibly or remotely
3 500 LONG-TERM SAFETY AND EFFICACY OF TAMSULOSIN FIG. 2. Mean total AUA symptom score and peak urine flow rate change from baseline in ITT population. Mean AUA symptom score baseline was Mean baseline Qmax was 10.1 ml per second. At 1 to 6 years AUA score change from baseline SD was 6.9, 6.9, 7.3, 7.3, 7.4 and 6.8. At 1 to 6 years Qmax change from baseline SD was 4.07, 3.96, 4.01, 4.13, 4.38 and 4.50 ml per second, respectively. *, statistically significant vs baseline (95% CI p 0.05). FIG. 3. Total AUA score mean change with tamsulosin from baseline in patients with at least 2 years of dosing, that is with potential to receive 6 years of tamsulosin, at start of trial Mean baseline score at year 0 was At 1 to 6 years AUA score change from baseline SD was 7.32, 6.90, 7.19, 7.11, 7.22 and 6.74, respectively. related) TEAEs decreased during the 6 years. During the whole study 95 patients (15.7%) discontinued tamsulosin due to TEAEs, which was less than the 18.7% who discontinued for other reasons, including protocol violations, nonstudy drug related reasons, poor compliance and personal reasons. Only 5 patients (0.8%) discontinued due to abnormal ejaculation and only 3 discontinued due to dizziness, postural hypotension and syncope (0.2%, 0.2% and 0.2%, respectively). Of the patients 29 (4.8%) experienced a serious AE considered related to tamsulosin treatment, including skin or prostate cancer, syncope, myocardial infarction and chest pain. During the study course there were 9 deaths. Only 1 death (due to heart arrest) was considered remotely related to drug therapy. Four of the 8 episodes of syncope were considered related to treatment. Table 2 lists TEAEs reported by 10% or greater of the patients. Only 30 patients (5%) had clinically significant PSA elevations from 4.0 or less to greater than 4.0 or greater than 4.0 to greater than 6.0 ng/ml throughout the whole 6-year experience. Of 122 patients 21 had clinically elevated PSA during the 4-year extension, of whom 11 discontinued treatment because PSA increased to 10 ng/ml or greater. Of the 604 patients 12 had prostate cancer during the 4-year extension. A total of 11 patients (1.8%) had AUR during the 6-year experience. No new cases developed during years 5 and 6. Only 1 patient withdrew from the study because of AUR. Eight patients (1.3%) experienced clinically significant orthostatic hypotension. DISCUSSION To our knowledge this study represents the longest clinical trial experience of -blocker therapy in patients with LUTS associated with BPH. Tamsulosin provided sustained relief of symptoms and urine flow for up to 6 years with high levels of safety and tolerability, and no decrease in the drug effect. This study corroborates and extends previous results regarding tamsulosin administration. 2 4 Significantly no new safety issues arose during the 4-year extension that had not been apparent in previous clinical trials. Consistent with previous tamsulosin studies, 2 4 discontinuation rates due to adverse events were low throughout the 6-year experience with the incidence of drug related TEAEs steadily decreasing. The discontinuation rate in this study due to TEAEs was 15.7%, which compares favorably with rates in other BPH drug trials.
4 LONG-TERM SAFETY AND EFFICACY OF TAMSULOSIN 501 TABLE 1. Changes from baseline in secondary efficacy parameters, QOL and PVR in 6 years in the ITT population Tamsulosin Experience, Yrs Baseline * Secondary efficacy parameters (vs baseline 95% CI p 0.05) No. pts AUA subsets: Mean irritative SE (range 0 15) Mean obstructive SE (range 0 20) % Nocturia more than 1/night (No.) Mean AUA bother score SE (range 0 28) (599) 44.7 (599) 41.2 (572) 45.2 (515) 48.2 (460) 45.9 (417) Boyarsky score: (462) (417) Mean total symptom SE (range 0 27) Mean irritative SE (range 0 12) Mean obstructive SE (range 0 15) % Nocturia more than (570) 42.1 (508) 42.4 (458) 41.2 (414) 45.0 (108) 1/night (No.) Mean urinary flow SE (ml/sec) QOL (vs baseline Wilcoxon signed rank test p 0.001) No. pts 597 (incomplete baseline evaluation in 3) Mean QOL score (median) (4.0) ( 2.0) ( 2.0) ( 1.0) ( 1.5) ( 2.0) ( 2.0) PVR (vs baseline 95% CI p 0.05 except yrs 4 & 6) No. pts Mean ml PVR SE ( ) ( ) ( ) ( ) ( ) ( ) (95% CI) * Potential 6-year experience at study entry in 159 patients.
5 502 LONG-TERM SAFETY AND EFFICACY OF TAMSULOSIN TABLE 2. New treatment emergent AEs reported by 10% or less of patients during 4-year extension AE No. Pts (%) Whole body: Infection 275 (45.5) Accidental injury 180 (29.8) Pain 150 (24.8) Headache 111 (18.4) Influenza syndrome 107 (17.7) Back pain 97 (16.1) Digestive system (dyspepsia) 74 (12.3) Musculoskeletal system (arthralgia) 80 (13.2) Nervous system (dizziness) 61 (10.1) Respiratory system: Rhinitis 155 (25.7) Pharyngitis 144 (23.8) Sinusitis 73 (12.1) Increased cough 66 (10.9) Urogenital system (prostatic disorder)* 68 (11.3) Safety population 604 patients. * Comprises various signs and symptoms of the prostate. When finasteride was compared with placebo in a 4-year study, 9 discontinuation rates due to TEAEs were high in each arms (34% and 42%, respectively). 8 In a 4-year doxazosin 10 study and a 42-month terazosin 11 study the therapeutic effect of each drug was maintained with time but dizziness led to discontinuation in 3.3% and 6.7% of patients, respectively. In addition, a significantly greater percent of patients who were treated vs those who received placebo (3.9 vs 0%) reported hypotension as an adverse reaction. 10 In contrast, in our study dizziness, postural hypotension and syncope led to discontinuation in only 0.2% of patients each. These low discontinuation rates may reflect tamsulosin selectivity for the 1A-receptor subtype. Abnormal ejaculation led to only 5 discontinuations (0.8% of patients), suggesting that patients did not perceive it to be as important as other events that led to discontinuation. 12 The low incidence of AUR in patients treated with tamsulosin for up to 6 years suggests that this agent may decrease the risk of AUR. The reported increase in PSA in the current study is consistent with observations in other long-term studies of patients with BPH. For example, in a placebo controlled finasteride trial elevated PSA occurred in 34% of the patients on placebo. 13 The low incidence of prostate cancer in our study, comparable to that in a placebo group of a similar population, 13 was achieved, although the tamsulosin population included some patients with high PSA who were at greater risk. Tamsulosin does not affect the risk of prostate carcinoma or detecting prostate cancer using PSA measurements. 14 CONCLUSIONS Tamsulosin has been shown to provide sustained significant relief of BPH symptoms for up to 6 years without a decrease in the drug effect. No new safety issues were reported during the 4-year extension study that had not been observed in previously published studies of shorter duration. The rate of discontinuation due to AEs was lower than in similar trials. The long-term safety and efficacy profiles of tamsulosin in patients with LUTS associated with BPH, corroborating and expanding results from previous short term clinical trials, support its usefulness as first line long-term therapy for LUTS associated with BPH. REFERENCES 1. Berry, S. J., Coffey, D. S., Walsh, P. C. and Ewing, L. L.: The development of human benign prostatic hyperplasia with age. J Urol, 132: 474, Narayan, P., Tewari, A. and Members of the United States Study Group: A second phase III multicenter placebo controlled study of 2 dosages of modified release tamsulosin in patients with symptoms of benign prostatic hyperplasia. J Urol, 160: 1701, Lepor, H.: Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Tamsulosin Investigator Group. Urology, 51: 892, Lepor, H.: Long-term evaluation of tamsulosin in benign prostatic hyperplasia: placebo-controlled, double-blind extension of phase III trial. Tamsulosin Investigator Group. Urology, 51: 901, Chapple, C. R., Wyndaele, J. J., Nordling, J., Boeminghaus, F., Ypma, A. F. and Abrams, P.: Tamsulosin, the first prostateselective alpha1a-adrenoceptor antagonist. A meta-analysis of two randomized, placebo-controlled, multicentre studies in patients with benign prostatic obstruction (symptomatic BPH). European Tamsulosin Study Group. Eur Urol, 29: 155, Lowe, F. C.: Coadministration of tamsulosin and three antihypertensive agents in patients with benign prostatic hyperplasia: pharmacodynamic effect. Clin Ther, 19: 730, Narayan, P. and Lepor, H.: Long-term, open-label, phase III multicenter study of tamsulosin in benign prostatic hyperplasia. Urology, 57: 466, Barry, M. J., Fowler, F. J., Jr., O Leary, M. P., Bruskewitz, R. C., Holtgrewe, H. L. and Mebust, W. K.: Measuring diseasespecific health status in men with benign prostatic hyperplasia. Measurement Committee of The American Urological Association. Med Care, suppl., 33: AS145, McConnell, J. D., Bruskewitz, R., Walsh, P., Andriole, G., Lieber, M., Holtgrewe, H. L. et al: The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N Engl J Med, 338: 557, Lepor, H., Kaplan, S. A., Klimberg, I., Mobley, D. F., Fawzy, A., Gaffney, M. et al: Doxazosin for benign prostatic hyperplasia: long-term efficacy and safety in hypertensive and normotensive patients. J Urol, 157: 525, Lepor, H.: Long-term efficacy and safety of terazosin in patients with benign prostatic hyperplasia. Terazosin Research Group. Urology, 45: 406, Hofner, K., Claes, H., De Reijke, T. M., Folkestad, B. and Speakman, M. J.: Tamsulosin 0.4 mg once daily: effect on sexual function in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol, 36: 335, Andriole, G. L., Guess, H. A., Epstein, J. I., Wise, H., Kadmon, D., Crawford, E. D. et al: Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer: results of a randomized, double-blind, placebocontrolled clinical trial. Pless Study Group. Proscar Long- Term Efficacy and Safety Study. Urology, 52: 195, Evans, C., Doyle, C. A. and Ranhosky, A.: PSA levels and occurrence of prostate cancer during long-term study (6 years) of treatment with tamsulosin for BPH. J Urol, suppl., 165: 382, abstract 1564, 2001
Increasing Awareness, Diagnosis, and Treatment of BPH, LUTS, and EP
Introduction to Enlarged Prostate E. David Crawford, MD Professor of Surgery (Urology) and Radiation Oncology Head, Urologic Oncology E. David Crawford Endowed Chair in Urologic Oncology University of
More informationH6D-MC-LVHR Clinical Study Report Synopsis Page LVHR Synopsis (LY450190)
H6D-MC-LVHR Clinical Study Report Synopsis Page 1 2. LVHR Synopsis H6D-MC-LVHR Clinical Study Report Synopsis Page 2 Clinical Study Report Synopsis: Study H6D-MC-LVHR Title of Study: A Randomized, Double-Blind,
More informationDiagnostic approach to LUTS in men. Prof Dato Dr. Zulkifli Md Zainuddin Consultant Urologist / Head Of Urology Unit UKM Medical Center
Diagnostic approach to LUTS in men Prof Dato Dr. Zulkifli Md Zainuddin Consultant Urologist / Head Of Urology Unit UKM Medical Center Classification of LUTS Storage symptoms Voiding symptoms Post micturition
More informationA Comparative Study of Efficacy and Safety Between Tamsulosin and Terazosin in the Treatment of Symptomatic Benign Prostatic Hyperplasia
Chattagram Maa-O-Shishu Hospital Medical College Journal Original Article A Comparative Study of Efficacy and Safety Between Tamsulosin and Terazosin in the Treatment of Symptomatic Benign Prostatic Hyperplasia
More informationThe Evolution of Combination Therapy. US men eligible for BPH treatment * with projected population changes
The Management of BPH & The Impact of Combination Therapy Results Combination of Avodart and Tamsulosin (CombAT) Medical Therapy of Prostate Symptoms (MTOPS) Dr. Jack Barkin, md, fics, facs, dabu, Mcert
More informationOffice Management of Benign Prostatic Enlargement
Focus on CME at McGill University Office Management of Benign Prostatic Enlargement Symptomatic benign prostate enlargement is a common medical problem encountered in our aging society. Watchful waiting,
More informationThe Journal of International Medical Research 2012; 40:
The Journal of International Medical Research 2012; 40: 899 908 Comparison of α-blocker Monotherapy and α-blocker Plus 5α-Reductase Inhibitor Combination Therapy Based on Prostate Volume for Treatment
More informationα-blocker Monotherapy and α-blocker Plus 5-Alpha-Reductase Inhibitor Combination Treatment in Benign Prostatic Hyperplasia; 10 Years Long-Term Results
www.kjurology.org http://dx.doi.org/10.4111/kju.2012.53.4.248 Voiding Dysfunction α-blocker Monotherapy and α-blocker Plus 5-Alpha-Reductase Inhibitor Combination Treatment in Benign Prostatic Hyperplasia;
More informationVoiding Dysfunction. Hyo Serk Lee, Sae Woong Kim 1, Seung-June Oh 2, Myung-Soo Choo 3, Kyu-Sung Lee
www.kjurology.org http://dx.doi.org/10.4111/kju.2012.53.3.178 Voiding Dysfunction Efficacy and Safety of Tamsulosin for Treating Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia:
More informationCombination Drug Therapy for Benign Prostatic Hyperplasia (BPH)
The Annals of African Surgery www.sskenya.org Combination Drug Therapy for Benign Prostatic Hyperplasia (BPH) Author: Oliech J.S. FRCS, Affiliation: Department of Surgery, University of Nairobi. P.O. Box
More informationDuring the past decade, numerous
Benign prostatic hyperplasia (BPH) is one of the most common diseases of aging men. It is estimated that by age 60 years, greater than 50% of men will have histologically documented evidence of the disease.
More informationThe Egyptian Journal of Hospital Medicine (January 2019) Vol. 74 (6), Page
The Egyptian Journal of Hospital Medicine (January 2019) Vol. 74 (6), Page 1377-1386 Evaluation of Silodosin in Comparison to Tamuslosin in Treatment of Benign Prostatic Hyperplasia with lower Urinary
More informationEffects of Low-Dose Tamsulosin on Sexual Function in Patients With Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia
www.kjurology.org http://dx.doi.org/10.4111/kju.2013.54.10.697 Sexual Dysfunction/Male Infertility Effects of Low-Dose Tamsulosin on Sexual Function in Patients With Lower Urinary Tract Symptoms Suggestive
More informationInternational Clinical Development Department, Yamanouchi Pharmaceutical Co., Ltd., 17 1 Hasune 3-chome, Itabashi-ku, Tokyo , Japan
192 Journal of Health Science, 47(2) 192 22 (21) Investigation of the Effects of Tamsulosin on Blood Pressure in Normotensive, Controlled Hypertensive, and Uncontrolled Hypertensive Men with Benign Prostatic
More informationOriginal Article Japanese Urological Association. International Journal of Urology (2006) 13,
Blackwell Publishing AsiaMelbourne, AustraliaIJUInternational Journal of Urology0919-81722006 Blackwell Publishing Asia Pty Ltd2006130014051409Original ArticleTamsulosin vs doxazosin in BPH D Rahardjo
More informationTherapeutic Strategies for Managing BPH Progression
european urology supplements 5 (2006) 997 1003 available at www.sciencedirect.com journal homepage: www.europeanurology.com Therapeutic Strategies for Managing BPH Progression John M. Fitzpatrick a, *,
More informationPRABHAKAR SINGH*, MANOJ INDURKAR, AMITA SINGH, PALLAVI INDURKAR
Academic Sciences International Journal of Current Pharmaceutical Research ISSN- 0975-7066 Vol 5, Issue 1, 2013 Research Article COMPARISON OF THE EFFICACY AND SAFETY OF TAMSULOSIN (0.4 V/S (and) FINASTERIDE
More informationThe Journal of International Medical Research 2005; 33:
The Journal of International Medical Research 2005; 33: 562 573 A Comparative Study on the Safety and Efficacy of Tamsulosin and Alfuzosin in the Management of Symptomatic Benign Prostatic Hyperplasia:
More informationThe treatment of benign prostatic hyperplasia with alpha blockers in men over the age of 80 years
British Journal of Urology (1997), 8, 875 879 The treatment of benign prostatic hyperplasia with alpha blockers in men over the age of 8 years S.A. KAPLAN, A.E. TE, E. IKEGUCHI and R.P. SANTAROSA Department
More informationClinicalTrials.gov Identifier: sanofi-aventis. Sponsor/company:
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: sanofi-aventis ClinicalTrials.gov
More informationMEDICAL THERAPY. Endocrine Approaches. Página 1 de 5.
Página 1 de 5 MEDICAL THERAPY Part of "32 - BENIGN PROSTATIC HYPERPLASIA" Use of pharmacologically defined and a variety of so-called alternative medications to attempt to improve BPH voiding dysfunction
More informationISSN: (Print) (Online) Journal homepage:
Archives of Andrology Journal of Reproductive Systems ISSN: 0148-5016 (Print) (Online) Journal homepage: http://www.tandfonline.com/loi/iaan19 CHANGE IN INTERNATIONAL PROSTATE SYMPTOM SCORE AFTER TRANSURETHRAL
More informationKey words: Lower Urinary Tract Symptoms (LUTS), Prostatic Hyperplasia, Alpha-1 Adrenoceptor Antagonists, Tamsulosin, Terazosin.
The Professional Medical Journal DOI: 10.17957/TPMJ/17.4102 ORIGINAL PROF-4102 PROSTATIC HYPERPLASIA; COMPARISON BETWEEN TAMSULOSIN AND TERAZOSIN FOR EFFICACY IN MEDICAL MANAGEMENT OF LOWER URINARY TRACT
More informationa 1 -adrenoceptor antagonist on uro owmetric parameters in patients with benign prostatic hyperplasia
Single dose methodology to assess the in uence of an a 1 -adrenoceptor antagonist on uro owmetric parameters in patients with benign prostatic hyperplasia S. P. Curtis, 1 I. Eardley, 2 M. Boyce, 3 P. Larson,
More informationBenign Prostatic Hyperplasia (BPH) Important Papers / Landmark. Vijayan Manogran
Benign Prostatic Hyperplasia (BPH) Important Papers / Landmark Studies Vijayan Manogran MTOPS & CombAT PLESS SMART ALTESS ALF-ONE VA PREDICT EPICS Landmark Studies MTOPS Medical Therapy of Prostatic Symptoms
More informationOriginal Article. Introduction. Methods. Abstract
Blackwell Science, LtdOxford, UKIJUInternational Journal of Urology0919-81722003 Blackwell Publishing Asia Pty LtdNovember 20031011587594Original ArticleUsefulness of a1-blockers in BPHI Ikemoto et al.
More informationChapter 4: Research and Future Directions
Chapter 4: Research and Future Directions Introduction Many of the future research needs listed in the 1994 Agency for Health Care Policy and Research (AHCPR) clinical practice guideline Benign Prostatic
More informationThe population of subjects which was statistically analyzed was the Intent-to-Treat population
Study No.: ARIB3003 (Year 1) Title: A Randomized, Double-Blind, Placebo-Controlled, Two-Year Parallel-Group Study of the Efficacy and Safety of GI198745 in the Treatment and Modification of Progression
More informationBenign Prostatic Hyperplasia. Jay Lee, MD, FRCSC Clinical Associate Professor University of Calgary
Benign Prostatic Hyperplasia Jay Lee, MD, FRCSC Clinical Associate Professor University of Calgary Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied,
More informationEVALUATION OF THE EFFICACY OF TADALAFIL IN IMPROVING LOWER URINARY TRACT SYMPTOMS IN PATIENTS WITH SYMPTOMATIC BENIGN PROSTATIC ENLARGEMENT
Basrah Journal Of Surgery EVALUATION OF THE EFFICACY OF TADALAFIL IN IMPROVING LOWER URINARY TRACT SYMPTOMS IN PATIENTS WITH SYMPTOMATIC BENIGN PROSTATIC ENLARGEMENT MB, ChB, FIBMS, Assistant Professor
More informationMini-Invasive Treatment in Urological Diseases Dott. Alberto Saita Responsabile Endourologia Istituto Clinico Humanitas - Rozzano
Dipartimento di Urologia Direttore Prof. Giorgio Guazzoni Mini-Invasive Treatment in Urological Diseases Dott. Alberto Saita Responsabile Endourologia Istituto Clinico Humanitas - Rozzano alberto.saita@humanitas.it
More informationOriginal Article - Voiding Dysfunction
www.kjurology.org http://dx.doi.org/10.4111/kju.2014.55.5.335 Original Article - Voiding Dysfunction http://crossmark.crossref.org/dialog/?doi=10.4111/kju.2014.55.5.335&domain=pdf&date_stamp=2014-05-16
More informationMANAGING BENIGN PROSTATIC HYPERTROPHY IN PRIMARY CARE DR GEORGE G MATHEW CONSULTANT FAMILY PHYSICIAN FELLOW IN SEXUAL & REPRODUCTIVE HEALTH
MANAGING BENIGN PROSTATIC HYPERTROPHY IN PRIMARY CARE DR GEORGE G MATHEW CONSULTANT FAMILY PHYSICIAN FELLOW IN SEXUAL & REPRODUCTIVE HEALTH INTRODUCTION (1) Part of male sexual reproductive organ Size
More informationRole of silodosin in patients with LUTS/BPE non responding to medical treatment with tamsulosin: a prospective, open-label, pilot study
European Review for Medical and Pharmacological Sciences 2017; 21: 4941-4945 Role of silodosin in patients with LUTS/BPE non responding to medical treatment with tamsulosin: a prospective, open-label,
More informationTreatment Patterns in Alpha-Blocker Therapy for Benign Prostatic Hyperplasia
510732JMHXXX10.1177/1557988313510732American Journal of Men s HealthSchoenfeld et al. research-article2013 Article Treatment Patterns in Alpha-Blocker Therapy for Benign Prostatic Hyperplasia American
More informationEfficacy and safety of tamsulosin OCAS
Original Article EFFICACY AND SAFETY OF TAMSULOSIN OCAS SPEAKMAN Efficacy and safety of tamsulosin OCAS MARK SPEAKMAN Taunton and Somerset Hospital, Taunton, UK The efficacy and safety of a new tablet
More informationHyoung Woo Kim, Dae Geun Moon, Hyun Min Kim, Jong Ho Hwang, Soon Chan Kim, Sam Geuk Nam, Jun Tag Park
www.kjurology.org http://dx.doi.org/10.4111/kju.2011.52.10.681 Voiding Dysfunction Effect of Shifting from Combination Therapy to Monotherapy of α-blockers or 5α-Reductase Inhibitors on Prostate Volume
More informationDIAGNOSED WITH BENIGN PROSTATIC HYPERPLASIA
Acta Poloniae Pharmaceutica ñ Drug Research, Vol. 74 No. 4 pp. 1247ñ1253, 2017 ISSN 0001-6837 Polish Pharmaceutical Society PHARMACOLOGY CLINICAL EVALUATION OF α-1-adrenolytics IN PATIENTS DIAGNOSED WITH
More informationKorean Urologist s View of Practice Patterns in Diagnosis and Management of Benign Prostatic Hyperplasia: A Nationwide Survey
Original Article DOI 10.3349/ymj.2010.51.2.248 pissn: 0513-5796, eissn: 1976-2437 Yonsei Med J 51(2):248-252, 2010 Korean Urologist s View of Practice Patterns in Diagnosis and Management of Benign Prostatic
More informationEuropean Urology Supplements 4 (2005) 33 44
European Urology Supplements European Urology Supplements 4 (2005) 33 44 Tamsulosin Oral Controlled Absorption System (OCAS) in Patients with Lower UrinaryTract Symptoms Suggestive of Benign Prostatic
More informationBenign Prostatic Hyperplasia (BPH):
Benign Prostatic Hyperplasia (BPH): Evidence Based Guidelines for Primary Care Providers Jeanne Martin, DNP, ANP-BC Objectives 1. Understand the pathophysiology and prevalence of BPH 2. Select the appropriate
More informationBenign Prostatic Hypertrophy (BPH) is the most
Medical treatment of benign prostatic hypertrophy There is little doubt that medical therapy has transformed the treatment of benign prostatic hypertrophy (BPH). The medical treatment of BPH continues
More informationChapter 3: Results of the Treatment Outcomes Analyses
Chapter 3: Results of the Treatment Outcomes Analyses Introduction To determine the appropriateness of individual therapies, as well as to develop practice recommendations, the American Urological Association
More informationAlpha antagonists from initial concept to routine clinical practice
european urology 50 (2006) 635 642 available at www.sciencedirect.com journal homepage: www.europeanurology.com Editorial 50th Anniversary Alpha antagonists from initial concept to routine clinical practice
More informationGuideline for the primary care management of male lower urinary tract symptoms
review Article GUIDELINES FOR LUTS M.J. SPEAKMAN et al. As my Comment in the first section of the journal suggested, the MTOPS results have offered the possibility to general practitioners of reducing
More informationRELATIONSHIPS BETWEEN AMERICAN UROLOGICAL ASSOCIATION SYMPTOM INDEX, PROSTATE VOLUME, PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA
American Urological Association symptom index for BPH RELATIONSHIPS BETWEEN AMERICAN UROLOGICAL ASSOCIATION SYMPTOM INDEX, PROSTATE VOLUME, AND DISEASE-SPECIFIC QUALITY OF LIFE QUESTION IN PATIENTS WITH
More informationManagement of LUTS. Simon Woodhams February 2012
Management of LUTS Simon Woodhams February 2012 The management of lower urinary tract symptoms (LUTS) in men Implementing NICE guidance May 2010 NICE clinical guideline 97 Background Lower urinary tract
More informationCorrespondence should be addressed to Yoshinori Tanaka;
Hindawi Advances in Urology Volume 2017, Article ID 4842025, 6 pages https://doi.org/10.1155/2017/4842025 Clinical Study The Persistence of Silodosin Monotherapy and the Reasons for Withdrawal from Treatment
More informationNew Treatment Modalities for Benign Prostatic Hyperplasia. Seung-June Oh, MD Department of Urology, Seoul National University Hospital
New Treatment Modalities for Benign Prostatic Hyperplasia Seung-June Oh, MD Department of Urology, Seoul National University Hospital Options for Treating BPH Pharmacotherapy blocker Agents for BPH + OAB
More informationDepartment of Urology, The University of Texas Southwestern Medical Center at Dallas, Dallas, TX
NEW PERSPECTIVES ON BPH 5- -Reductase Inhibitors Prevent the Progression of Benign Prostatic Hyperplasia Claus G. Roehrborn, MD Department of Urology, The University of Texas Southwestern Medical Center
More informationProfile of Silodosin. Francesco Montorsi * Article info. Abstract
EUROPEAN UROLOGY SUPPLEMENTS 9 (2010) 491 495 available at www.sciencedirect.com journal homepage: www.europeanurology.com Profile of Silodosin Francesco Montorsi * Department of Urology, University Vita-Salute
More informationUV-2005/01. Chronic Prostatitis and Chronic Pelvic Pain Syndrom (CP/CPPS) Karl-Bickleder-Str. 44C Straubing - Germany
SYNOPSIS UV-2005/01 Title: Short Title: Indication: Phase: Study Code: Study Director Co-ordinating Investigator: Study Centres: Multicentre, randomised, double-blind, placebo-controlled clinical study
More informationIs Tamsulosin 0.2 mg Effective and Safe as a First-Line Treatment Compared with Other Alpha Blockers?: A Meta-Analysis and a Moderator Focused Study
Original Article Yonsei Med J 2016 Mar;57(2):407-418 pissn: 0513-5796 eissn: 1976-2437 Is Tamsulosin 0.2 mg Effective and Safe as a First-Line Treatment Compared with Other Alpha Blockers?: A Meta-Analysis
More informationMedical Therapy for Benign Prostatic Hyperplasia Present and Future Impact
REPORTS Medical Therapy for Benign Prostatic Hyperplasia Present and Future Impact Muta M. Issa, MD, MBA; Timothy S. Regan, BPharm, RPh, CPh Abstract The purpose of this manuscript is to provide clinicians,
More informationAbstract. Key words Trial without catheter, Acute urinary retention, Benign prostatic hyperplasia, Introduction
The role of sustained-released alfuzosin in the treatment of acute urinary retention Mohamed Fawzi Ahmed. Department of Surgery, Ninevah College of Medicine, University of Mosul. Abstract To see whether
More informationMMM. Topic The use of Tadalafil 5mg daily for the treatment of BPH-LUTS
Dr Tan & Partners MMM Vol. 1 No. 1 Morbidity & Mortality Meeting 14 th November 2014 Introduction Topic The use of Tadalafil 5mg daily for the treatment of BPH-LUTS Tadalafil 5mg daily is a well established
More informationL ower urinary tract symptoms (LUTS) are a major health problem and are prevalent in men aged.45 years1 3.
OPEN SUBJECT AREAS: UROGENITAL DISEASES DRUG DEVELOPMENT Received 23 October 2013 Accepted 15 January 2014 Published 4 February 2014 Correspondence and requests for materials should be addressed to P.H.
More informationClinical Trial Synopsis TL-OPI-525, NCT#
Clinical Trial Synopsis, NCT#00762736 Title of Study: A Phase II, Double-Blind, Randomized, Placebo-Controlled, Proof-of-Concept Study of the Efficacy, Safety, and Tolerability of Pioglitazone HCl (ACTOS
More informationRole of herbal drugs in the management of benign prostatic hyperplasia: Clinical trial to evaluate the efficacy and safety of Himplasia
[Medicine Update (2003): 11(2), 55-58] Role of herbal drugs in the management of benign prostatic hyperplasia: Clinical trial to evaluate the efficacy and safety of Himplasia Arora, R.P., CMO, Rajiba L.
More informationBPH: a present and future perspective on health impact
BPH: a present and future perspective on health impact Burden of disease in men with moderate LUTS Dalibor Pacík This presentation is financially supported by GlaxoSmithKline. CZ/DUTT/0019/12 Men with
More informationCurrent drug management of BPH in primary care Claire Taylor MRCS, Charlotte Foley MRCS and Roger Kirby MA, MD, FRCS Urol
Drug review BPH Current drug management of BPH in primary care Claire Taylor MRCS, Charlotte Foley MRCS and Roger Kirby MA, MD, FRCS Urol Skyline Imaging Ltd The range of drug treatments for BPH, alone
More informationMedical therapy options for aging men with benign prostatic hyperplasia: focus on alfuzosin 10 mg once daily
REVIEW Medical therapy options for aging men with benign prostatic hyperplasia: focus on alfuzosin 10 mg once daily Claus G Roehrborn 1 Raymond C Rosen 2 1 Department of Urology, University of Texas Southwestern
More informationSilodosin versus naftopidil for the treatment of benign prostatic hyperplasia: A multicenter randomized trial
The study protocol was approved by the ethics committee and institutional review board of Nihon University School of Medicine. Written informed consent was obtained from all patients. From December 2007
More informationBenign Prostatic Hyperplasia. Management of Benign Prostatic Hyperplasia. Goals of Therapy
Benign Prostatic Hyperplasia Management of Benign Prostatic Hyperplasia Goals of Therapy Improve or abolish lower urinary tract symptoms (LUTS) Prevent or delay clinical progression of benign prostatic
More informationSystematic Review of Combination Drug Therapy for Non-neurogenic Male Lower Urinary Tract Symptoms
EUROPEAN UROLOGY 64 (2013) 228 243 available at www.sciencedirect.com journal homepage: www.europeanurology.com Platinum Priority Collaborative Review Benign Prostatic Hyperplasia Editorial by Herbert
More informationVictoria Sharp, MD, MBA, FAAFP. Clinical Professor of Urology and Family Medicine
Victoria Sharp, MD, MBA, FAAFP Clinical Professor of Urology and Family Medicine Victoria Sharp, MD, MBA, FAAFP Market Chief Medial Officer AmeriHealth Caritas Family of Companies Office phone: (515) 330-3740
More informationEffects of prostatic inflammation on LUTS and alpha blocker treatment outcomes
ORIGINAL ARTICLE Vol. 40 (3): 356-366, May - June, 2014 doi: 10.1590/S1677-5538.IBJU.2014.03.09 Effects of prostatic inflammation on LUTS and alpha blocker treatment outcomes Ha Na Lee 1, Tae-Hyoung Kim
More informationThe Hallmarks of BPH Progression and Risk Factors
European Urology Supplements European Urology Supplements 2 (23) 2 7 The Hallmarks of BPH Progression and Risk Factors M. Emberton * Institute of Urology and Nephrology, University College London, 48 Riding
More informationPROSTATIC ARTERY EMBOLISATION (PAE) FOR BENIGN PROSTATIC HYPERPLASIA. A Minimally Invasive Innovative Treatment
PROSTATIC ARTERY EMBOLISATION (PAE) FOR BENIGN PROSTATIC HYPERPLASIA A Minimally Invasive Innovative Treatment What is the prostate? The prostate is an accessory organ of the male reproductive system.
More informationBalancing clinical outcomes and quality of life aspects in the treatment of LUTS/BPH van Dijk, M.M.
UvA-DARE (Digital Academic Repository) Balancing clinical outcomes and quality of life aspects in the treatment of LUTS/BPH van Dijk, M.M. Link to publication Citation for published version (APA): van
More informationWill Medical Management of Benign Prostatic Hyperplasia Result in Better or Worse Sexual Function in Men?
Urol Sci 2011;22(1):14 18 MINI REVIEW Will Medical Management of Benign Prostatic Hyperplasia Result in Better or Worse Sexual Function in Men? Thomas I.S. Hwang 1,2,3 * 1 Shin Kong WHS Hospital, Taipei,
More informationNIH Public Access Author Manuscript J Urol. Author manuscript; available in PMC 2010 May 4.
NIH Public Access Author Manuscript Published in final edited form as: J Urol. 2009 December ; 182(6): 2819 2824. doi:10.1016/j.juro.2009.08.086. Intravesical Prostatic Protrusion in Men in Olmsted County,
More informationVOIDING DYSFUNCTION IN ELDERLY MALE CURRENT STATUS
VOIDING DYSFUNCTION IN ELDERLY MALE CURRENT STATUS DR. FRANCIS LEE Voiding dysfunction Storage Emptying Common voiding dysfunction in elderly male Emptying BPH Storage Incontinence Overactive bladder Post-prostatectomy
More informationSerum Prostate-Specific Antigen as a Predictor of Prostate Volume in the Community: The Krimpen Study
european urology 51 (2007) 1645 1653 available at www.sciencedirect.com journal homepage: www.europeanurology.com Benign Prostatic Hyperplasia Serum Prostate-Specific Antigen as a Predictor of Prostate
More informationChapter 3: Results of the Treatment Outcomes Analyses
Chapter 3: Results of the Treatment Outcomes Analyses TABLE OF CONTENTS INTRODUCTION... 3 WATCHFUL WAITING... 11 STUDY OUTCOMES... 11 MEDICAL THERAPIES... 13 ALPHA-ADRENERGIC ANTAGONISTS (ALPHA-BLOCKERS)...
More informationBPH with persistently elevated PSA 아주대학교김선일
BPH with persistently elevated PSA 아주대학교김선일 PSA in BPH: present status AUA & EAU BPH guideline: PSA: recommended test AUA practice guideline committee. J Urol 2003;170:530 Madersbacher. Eur Urol 2004;46:547
More informationCan men with prostates sized 80 ml or larger be managed conservatively?
Original Article - Lower Urinary Tract Dysfunction Investig Clin Urol 2017;58:359-364. pissn 2466-0493 eissn 2466-054X Can men with prostates sized 80 ml or larger be managed conservatively? Alvin Lee,
More informationThe Enlarged Prostate Symptoms, Diagnosis and Treatment
The Enlarged Prostate Symptoms, Diagnosis and Treatment MAC00031-01 Rev G Financial support for this seminar has been provided by NeoTract, Inc., the manufacturer of the UroLift System. 1 Today s Agenda
More informationThe Risk of Fracture with Taking Alpha Blockers for Treating Benign Prostatic Hyperplasia
J Prev Med Public Health 2009;42(3):165-170 DOI: 103961/jpmph2009423165 The Risk of Fracture with Taking Alpha Blockers for Treating Benign Prostatic Hyperplasia Joongyub Lee 1) Nam-Kyoung Choi 13) Sun-Young
More informationTzu Chi Medical Journal
Tzu Chi Medical Journal 25 (2013) 98e102 Contents lists available at SciVerse ScienceDirect Tzu Chi Medical Journal journal homepage: www.tzuchimedjnl.com Original Article First-line antimuscarinic monotherapy
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationEfficacy of Silodosin for Relieving Benign Prostatic Obstruction: Prospective Pressure Flow Study
Efficacy of Silodosin for Relieving Benign Prostatic Obstruction: Prospective Pressure Flow Study Yoshihisa Matsukawa,* Momokazu Gotoh, Tomonori Komatsu, Yasuhito Funahashi, Naoto Sassa and Ryohei Hattori
More informationTamsulosin sustained release preparation in patients of lower urinary tract symptoms due to benign prostatic hyperplasia
J. Acad. Indus. Res. Vol. 1(11) April 2013 679 RESEARCH MANUSCRIPT ISSN: 2278-5213 Tamsulosin sustained release preparation in patients of lower urinary tract symptoms due to benign prostatic hyperplasia
More informationStudy No. 178-CL-008 Report Final Version, 14 Dec 2006 Reissued Version, 18 Jul 2011 Astellas Pharma Europe B.V. Page 13 of 122
Page 13 of 122 3 SYNOPSIS Title of study: (International) Study No: A randomized, double-blind, parallel group, proof-of-concept study of in comparison with placebo and tolterodine in patients with symptomatic
More informationClinical Trial Synopsis TL-OPI-518, NCT#
Clinical Trial Synopsis, NCT# 00225264 Title of Study: A Double-Blind, Randomized, Comparator-Controlled Study in Subjects With Type 2 Diabetes Mellitus Comparing the Effects of Pioglitazone HCl vs Glimepiride
More informationRecommended drug treatment of BPH in primary care Claire Taylor MRCS, Charlotte Foley MRCS and Roger Kirby MA, MD, FRCS Urol
Drug review BPH Recommended drug treatment of BPH in primary care Claire Taylor MRCS, Charlotte Foley MRCS and Roger Kirby MA, MD, FRCS Urol Skyline Imaging Ltd The development of safe and effective drugs
More informationLiterature Scan: Drugs for BPH
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationIJBCP International Journal of Basic & Clinical Pharmacology
Print ISSN: 2319-2003 Online ISSN: 2279-0780 IJBCP International Journal of Basic & Clinical Pharmacology DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20160772 Research Article Efficacy and safety of
More informationBenign Prostatic Hyperplasia and Enlarged Prostate Guidelines: How They Can Be Useful to Primary Care
Volume 1, Number 1 Weill Medical College of Cornell University Reports on Men s Urologic Health 1 Editor: Steven A. Kaplan, MD, Professor of Urology, and Chief, Institute for Bladder and Prostate Health,
More informationREVIEW The utility of serum prostatic-specific antigen in the management of men with benign prostatic hyperplasia
(2008) 20, S19 S26 & 2008 Nature Publishing Group All rights reserved 0955-9930/08 $30.00 www.nature.com/ijir REVIEW The utility of serum prostatic-specific antigen in the management of men with benign
More informationIndex. urologic.theclinics.com. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Ablative therapies, transurethral needle ablation, Adverse events, sexual side effects of BPH Aging, and incidence of BPH associated with
More informationREVIEW The role of combination medical therapy in benign prostatic hyperplasia
(2008) 20, S33 S43 & 2008 Nature Publishing Group All rights reserved 0955-9930/08 $30.00 www.nature.com/ijir REVIEW The role of combination medical therapy in benign prostatic hyperplasia Department of
More informationImpact of Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia Treatment with Tamsulosin and Solifenacin Combination Therapy on Erectile Function
www.kjurology.org DOI:10.4111/kju.2011.52.1.49 Sexual Dysfunction Impact of Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia Treatment with Tamsulosin and Solifenacin Combination Therapy on Erectile
More informationLast Review Status/Date: December Summary
Section: Surgery Effective Date: January 15, 2016 Subject: Prostatic Urethral Lift Page: 1 of 9 Last Review Status/Date: December 2015 Summary Benign prostatic hyperplasia (BPH) is a common condition in
More informationregimens. Data may differ from published or presented data and are limited information provided here. The results from a single trial need
Study Code: BCSK/05/Pro-BPH/001 EudraCT number: 2006-003532-30 This Summary of Clinical Study Report is provided for patients and healthcare professionals to demonstrate the transparency efforts of the
More informationSummary ID# Clinical Study Summary: Study B4Z-MC-LYCL
CT Registry ID#8226 Page 1 Summary ID# 8226. Clinical Study Summary: Study B4Z-MC-LYCL Guiding Dose Increases in Patients Incompletely Responsive to Usual Doses of Atomoxetine by Determining Plasma Atomoxetine
More informationThe New England Journal of Medicine
The New England Journal of Medicine Copyright, 1996, by the Massachusetts Medical Society VOLUME 335 A UGUST, 1996 NUMBER 8 THE EFFICACY OF TERAZOSIN, FINASTERIDE, OR BOTH IN BENIGN PROSTATIC HYPERPLASIA
More informationSILOFAST Capsules (Silodosin)
Published on: 10 Jul 2014 SILOFAST Capsules (Silodosin) Composition SILOFAST-4 Capsules Each hard gelatin capsule contains: Silodosin 4 mg Approved colours used in capsule shell SILOFAST-8 Capsules Each
More information